A randomised, open-label, phase II study of tobemstomig combinations in patients with previously untreated advanced clear-cell renal cell carcinoma

This publication has 16 references indexed in Scilit:

• Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial
  Nature Medicine, 2025
• 7MO: A phase II trial of tobemstomig (tobe) + platinum-based chemotherapy (chemo) vs pembrolizumab (pembro) + chemo in patients (pts) with untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)
  Journal of Thoracic Oncology, 2025
• Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data
  Cancer Immunology, Immunotherapy, 2024
• Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
  European Urology, 2023
• Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
  New England Journal of Medicine, 2022
• Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy
  Nature Communications, 2021
• Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
  Cancer Cell, 2021
• Progressive immune dysfunction with advancing disease stage in renal cell carcinoma
  Cancer Cell, 2021
• Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
  Nature Medicine, 2020
• Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
  New England Journal of Medicine, 2019